Danoprevir: Interim Phase II data

Interim data from 38 treatment-naive, non-cirrhotic patients with HCV genotype 1 infection in the Taiwanese Phase II EVEREST trial showed that danoprevir plus ravidasvir for 12 weeks led to an end of ...